請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23635完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 鄧哲明 | |
| dc.contributor.author | Chung-Chun Chen | en |
| dc.contributor.author | 陳鐘珺 | zh_TW |
| dc.date.accessioned | 2021-06-08T05:06:35Z | - |
| dc.date.copyright | 2011-10-07 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2011-07-04 | |
| dc.identifier.citation | Aggarwal, B.B., A.B. Kunnumakkara, K.B. Harikumar, S.R. Gupta, S.T. Tharakan, C. Koca, S. Dey, and B. Sung. 2009. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann. N. Y. Acad. Sci. 1171:59-76.
Allan, L.A., N. Morrice, S. Brady, G. Magee, S. Pathak, and P.R. Clarke. 2003. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol. 5:647-654. Andreassen, P.R., F.B. Lacroix, O.D. Lohez, and R.L. Margolis. 2001. Neither p21WAF1 nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells. Cancer Res. 61:7660-7668. Bischoff, J.R., and G.D. Plowman. 1999. The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 9:454-459. Blagden, S.P., and D.M. Glover. 2003. Polar expeditions--provisioning the centrosome for mitosis. Nat Cell Biol. 5:505-511. Blagosklonny, M.V. 2007. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle. 6:70-74. Blalock, W.L., C. Weinstein-Oppenheimer, F. Chang, P.E. Hoyle, X.Y. Wang, P.A. Algate, R.A. Franklin, S.M. Oberhaus, L.S. Steelman, and J.A. McCubrey. 1999. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia. 13:1109-1166. Bowman, T., R. Garcia, J. Turkson, and R. Jove. 2000. STATs in oncogenesis. Oncogene. 19:2474-2488. Buxbaum, J.L., and M.A. Eloubeidi. 2010. Molecular and clinical markers of pancreas cancer. JOP. 11:536-544. Calvo, F., L. Agudo-Ibanez, and P. Crespo. 2010. The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies. Bioessays. 32:412-421. Casenghi, M., R. Mangiacasale, M. Tuynder, P. Caillet-Fauquet, A. Elhajouji, P. Lavia, S. Mousset, M. Kirsch-Volders, and E. Cundari. 1999. p53-independent apoptosis and p53-dependent block of DNA rereplication following mitotic spindle inhibition in human cells. Exp. Cell Res. 250:339-350. Cassimeris, L. 2002. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr. Opin. Cell Biol. 14:18-24. Castedo, M., J.L. Perfettini, T. Roumier, and G. Kroemer. 2002. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ. 9:1287-1293. Cohen, S.J., and N.J. Meropol. 2002. Drug development in pancreatic cancer: finally, biology begets therapy. Int J Gastrointest Cancer. 32:91-106. Darnell, J.E., Jr. 2002. Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2:740-749. De Falco, M., and A. De Luca. 2010. Cell cycle as a target of antineoplastic drugs. Curr. Pharm. Des. 16:1417-1426. Decordier, I., E. Cundari, and M. Kirsch-Volders. 2008. Mitotic checkpoints and the maintenance of the chromosome karyotype. Mutat Res. 651:3-13. Deer, E.L., J. Gonzalez-Hernandez, J.D. Coursen, J.E. Shea, J. Ngatia, C.L. Scaife, M.A. Firpo, and S.J. Mulvihill. 2010. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 39:425-435. Deveraux, Q.L., R. Takahashi, G.S. Salvesen, and J.C. Reed. 1997. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 388:300-304. Ditchfield, C., V.L. Johnson, A. Tighe, R. Ellston, C. Haworth, T. Johnson, A. Mortlock, N. Keen, and S.S. Taylor. 2003. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 161:267-280. Garnett, M.J., and R. Marais. 2004. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 6:313-319. Green, D.R., and G. Kroemer. 2004. The pathophysiology of mitochondrial cell death. Science. 305:626-629. Harada, H., B. Quearry, A. Ruiz-Vela, and S.J. Korsmeyer. 2004. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci U S A. 101:15313-15317. Hauf, S., R.W. Cole, S. LaTerra, C. Zimmer, G. Schnapp, R. Walter, A. Heckel, J. van Meel, C.L. Rieder, and J.M. Peters. 2003. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 161:281-294. Hidalgo, M. 2010. Pancreatic cancer. N Engl J Med. 362:1605-1617. Honore, S., E. Pasquier, and D. Braguer. 2005. Understanding microtubule dynamics for improved cancer therapy. Cell. Mol. Life Sci. 62:3039-3056. Hoyle, P.E., P.W. Moye, L.S. Steelman, W.L. Blalock, R.A. Franklin, M. Pearce, H. Cherwinski, E. Bosch, M. McMahon, and J.A. McCubrey. 2000. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia. 14:642-656. Igney, F.H., and P.H. Krammer. 2002. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2:277-288. Ivanov, A., M.S. Cragg, J. Erenpreisa, D. Emzinsh, H. Lukman, and T.M. Illidge. 2003. Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. J Cell Sci. 116:4095-4106. Jaganathan, S., P. Yue, and J. Turkson. 2010. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther. 333:373-381. Jordan, M.A., and L. Wilson. 2004. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253-265. Kalser, M.H., and S.S. Ellenberg. 1985. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 120:899-903. Kirsch-Volders, M., A. Vanhauwaert, M. De Boeck, and I. Decordier. 2002. Importance of detecting numerical versus structural chromosome aberrations. Mutat. Res. 504:137-148. Kischkel, F.C., S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P.H. Krammer, and M.E. Peter. 1995. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14:5579-5588. Kops, G.J., B.A. Weaver, and D.W. Cleveland. 2005. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 5:773-785. Krammer, P.H., R. Arnold, and I.N. Lavrik. 2007. Life and death in peripheral T cells. Nat Rev Immunol. 7:532-542. Lavrik, I., A. Golks, and P.H. Krammer. 2005a. Death receptor signaling. J Cell Sci. 118:265-267. Lavrik, I.N. 2010. Systems biology of apoptosis signaling networks. Curr. Opin. Biotechnol. 21:551-555. Lavrik, I.N., A. Golks, and P.H. Krammer. 2005b. Caspases: pharmacological manipulation of cell death. J Clin Invest. 115:2665-2672. Li, J., M.G. Wientjes, and J.L. Au. 2010. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J. 12:223-232. Lopez-Perez, M., and E.P. Salazar. 2006. A role for the cytoskeleton in STAT5 activation in MCF7 human breast cancer cells stimulated with EGF. Int J Biochem Cell Biol. 38:1716-1728. Ma, X., and P.P. Sayeski. 2007. Identification of tubulin as a substrate of Jak2 tyrosine kinase and its role in Jak2-dependent signaling. Biochemistry. 46:7153-7162. MacLachlan, T.K., N. Sang, and A. Giordano. 1995. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expr. 5:127-156. Malumbres, M. 2007. Cyclins and related kinases in cancer cells. J BUON. 12 Suppl 1:S45-52. Mandal, P.K., D. Limbrick, D.R. Coleman, G.A. Dyer, Z. Ren, J.S. Birtwistle, C. Xiong, X. Chen, J.M. Briggs, and J.S. McMurray. 2009. Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling. J Med Chem. 52:2429-2442. Masuda, A., K. Maeno, T. Nakagawa, H. Saito, and T. Takahashi. 2003. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am. J. Pathol. 163:1109-1116. Matsumura, S., F. Toyoshima, and E. Nishida. 2007. Polo-like kinase 1 facilitates chromosome alignment during prometaphase through BubR1. J. Biol. Chem. 282:15217-15227. McCubrey, J.A., L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W. Wong, F. Chang, B. Lehmann, D.M. Terrian, M. Milella, A. Tafuri, F. Stivala, M. Libra, J. Basecke, C. Evangelisti, A.M. Martelli, and R.A. Franklin. 2007. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263-1284. McDaid, H.M., and S.B. Horwitz. 2001. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol. Pharmacol. 60:290-301. McGrogan, B.T., B. Gilmartin, D.N. Carney, and A. McCann. 2008. Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophys. Acta. 1785:96-132. Michaud, D.S. 2004. Epidemiology of pancreatic cancer. Minerva Chir. 59:99-111. Mitchison, T., and M. Kirschner. 1984. Dynamic instability of microtubule growth. Nature. 312:237-242. Mollinedo, F., and C. Gajate. 2003. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis. 8:413-450. Moon, D.O., M.O. Kim, Y.H. Choi, and G.Y. Kim. 2008. beta-Sitosterol induces G2/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI3K/Akt signaling pathways. Cancer Lett. 264:181-191. Morse, D.L., H. Gray, C.M. Payne, and R.J. Gillies. 2005. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther. 4:1495-1504. Ng, D.C., B.H. Lin, C.P. Lim, G. Huang, T. Zhang, V. Poli, and X. Cao. 2006. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol. 172:245-257. Niederhuber, J.E., M.F. Brennan, and H.R. Menck. 1995. The National Cancer Data Base report on pancreatic cancer. Cancer. 76:1671-1677. Nigg, E.A. 2001. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2:21-32. Rieder, C.L., and H. Maiato. 2004. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell. 7:637-651. Roninson, I.B., E.V. Broude, and B.D. Chang. 2001. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 4:303-313. Sausville, E.A. 2005. Cell cycle regulatory kinase modulators: interim progress and issues. Curr Top Med Chem. 5:1109-1117. Sherr, C.J., and J.M. Roberts. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501-1512. Silver, D.L., H. Naora, J. Liu, W. Cheng, and D.J. Montell. 2004. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 64:3550-3558. Steelman, L.S., S.C. Pohnert, J.G. Shelton, R.A. Franklin, F.E. Bertrand, and J.A. McCubrey. 2004. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 18:189-218. Stewart, Z.A., D. Mays, and J.A. Pietenpol. 1999. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res. 59:3831-3837. Strosberg, J., N. Gardner, and L. Kvols. 2009. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas. 38:255-258. Sun, V. 2010. Update on pancreatic cancer treatment. Nurse Pract. 35:16-22; quiz 22-13. Tamemoto, H., T. Kadowaki, K. Tobe, K. Ueki, T. Izumi, Y. Chatani, M. Kohno, M. Kasuga, Y. Yazaki, and Y. Akanuma. 1992. Biphasic activation of two mitogen-activated protein kinases during the cell cycle in mammalian cells. J Biol Chem. 267:20293-20297. Tao, W., V.J. South, Y. Zhang, J.P. Davide, L. Farrell, N.E. Kohl, L. Sepp-Lorenzino, and R.B. Lobell. 2005. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell. 8:49-59. Thome, M., P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, C. Mattmann, K. Burns, J.L. Bodmer, M. Schroter, C. Scaffidi, P.H. Krammer, M.E. Peter, and J. Tschopp. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 386:517-521. Turkson, J., D. Ryan, J.S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laudano, S. Sebti, A.D. Hamilton, and R. Jove. 2001. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 276:45443-45455. Vader, G., R.H. Medema, and S.M. Lens. 2006. The chromosomal passenger complex: guiding Aurora-B through mitosis. J. Cell Biol. 173:833-837. van Vugt, M.A., B.C. van de Weerdt, G. Vader, H. Janssen, J. Calafat, R. Klompmaker, R.M. Wolthuis, and R.H. Medema. 2004. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J. Biol. Chem. 279:36841-36854. Verde, F., M. Dogterom, E. Stelzer, E. Karsenti, and S. Leibler. 1992. Control of microtubule dynamics and length by cyclin A- and cyclin B-dependent kinases in Xenopus egg extracts. J. Cell Biol. 118:1097-1108. Verdoodt, B., I. Decordier, K. Geleyns, M. Cunha, E. Cundari, and M. Kirsch-Volders. 1999. Induction of polyploidy and apoptosis after exposure to high concentrations of the spindle poison nocodazole. Mutagenesis. 14:513-520. Wahl, A.F., K.L. Donaldson, C. Fairchild, F.Y. Lee, S.A. Foster, G.W. Demers, and D.A. Galloway. 1996. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2:72-79. Walker, R.A., E.T. O'Brien, N.K. Pryer, M.F. Soboeiro, W.A. Voter, H.P. Erickson, and E.D. Salmon. 1988. Dynamic instability of individual microtubules analyzed by video light microscopy: rate constants and transition frequencies. J. Cell Biol. 107:1437-1448. Walker, S.R., M. Chaudhury, E.A. Nelson, and D.A. Frank. 2010. Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol. 78:903-908. Weaver, B.A., and D.W. Cleveland. 2005. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell. 8:7-12. Winey, M., and B.J. Huneycutt. 2002. Centrosomes and checkpoints: the MPS1 family of kinases. Oncogene. 21:6161-6169. Woods, D., D. Parry, H. Cherwinski, E. Bosch, E. Lees, and M. McMahon. 1997. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol. 17:5598-5611. Wright, J.H., E. Munar, D.R. Jameson, P.R. Andreassen, R.L. Margolis, R. Seger, and E.G. Krebs. 1999. Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts. Proc Natl Acad Sci U S A. 96:11335-11340. Yan, Y., R.S. Spieker, M. Kim, S.M. Stoeger, and K.H. Cowan. 2005. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene. 24:3285-3296. Yoshida, H., C.J. Hastie, H. McLauchlan, P. Cohen, and M. Goedert. 2004. Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). J. Neurochem. 90:352-358. Youle, R.J., and A. Strasser. 2008. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47-59. Yu, H., D. Pardoll, and R. Jove. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 9:798-809. Zha, J., H. Harada, E. Yang, J. Jockel, and S.J. Korsmeyer. 1996. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 87:619-628. Zhou, J., and P. Giannakakou. 2005. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 5:65-71. Zhou, J., J. Yao, and H.C. Joshi. 2002. Attachment and tension in the spindle assembly checkpoint. J. Cell Sci. 115:3547-3555. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23635 | - |
| dc.description.abstract | 胰臟癌的癌症死亡率排名在台灣為第九位，由於此癌症不容易在早期被發現，所以患者的存活率極低。本研究的目的是探討化學合成新藥物LTP-1對於人類胰臟癌細胞的藥理機轉。首先，在SRB和MTT實驗中發現LTP-1能有效抑制胰臟癌細胞的生長與存活；接著，我們利用PI染色合併流式細胞儀分析發現LTP-1在短時間處理能讓胰臟癌細胞停滯在G2/M期；除此之外，LTP-1也會抑制微管聚合，並使M期指標蛋白MPM2和Histone-3 Ser10磷酸化增加；同時，我們也發現LTP-1在胰臟癌細胞中會抑制STAT3的磷酸化，不過這與LTP-1促使細胞週期停在G2/M期無關。另外，LTP-1也會活化ERK，但給予ERK抑制劑PD98059並不會抑制LTP-1所造成的G2/M期停滯。而長期給予LTP-1則會讓細胞形成多倍體及增加subG1的細胞數，也會導致PARP cleavage並活化caspase-3、-7、-8、-9。最後，在小鼠腫瘤異體移植實驗中證實LTP-1能抑制人類胰臟癌細胞AsPC-1的生長。綜合以上結果，LTP-1能改變微管蛋白的動態，進而使細胞週期停滯在G2/M期，最終將導致細胞形成多倍體並經由caspase 活化來造成細胞凋亡，所以LTP-1具有潛力發展成為新的抗癌藥物。 | zh_TW |
| dc.description.abstract | Pancreatic cancer is the ninth cause of cancer deaths in Taiwan. Pancreatic cancer patients are always diagnosed at an advanced stage resulting in poor survival rates. The purpose of this study is to determine the mechanism of action of a new synthetic compound LTP-1 on human pancreatic cancer in vitro and in vivo. The study demonstrated that LTP-1 inhibited cell growth and viability in the AsPC1 and PANC-1 human pancreatic cancer cells. Using flow cytometry analysis, we found that short-term treatment of LTP-1 could significantly induce G2/M arrest in the cell cycle progression. The data showed that LTP-1 could disrupt microtubule dynamics and induce phosphorylation of two mitotic markers, MPM2 and Histone-3 Ser10, in a concentration-dependent manner. Furthermore, LTP-1 inhibited STAT3 tyrosine phosphorylation and induced ERK activation; however, both of which did not contribute to G2/M arrest. Long-term treatment of LTP-1 induced polyploidy and triggered them to undergo apoptosis through catalytic cleavage of caspase-3, -7, -8, -9, and poly (ADP-ribose) polymerase (PARP). Finally, we used an in vivo xenograft mouse model to demonstrate that LTP-1 suppressed pancreatic adenocarcinoma AsPC-1 growth. In summary, the results suggest that LTP-1 can change microtubule dynamics, and leading to G2/M arrest of the cell cycle which ultimately causes polyploidy and apoptosis through the intrinsic and extrinsic apoptotic pathways. The study provides evidence that LTP-1 is a potential anticancer agent for further development. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T05:06:35Z (GMT). No. of bitstreams: 1 ntu-100-R98443018-1.pdf: 4139307 bytes, checksum: c318758eeaeca967fe2b973dd88fa6e6 (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | 目錄
口試委員會審定書 I 誌謝 II 縮寫表 III 中文摘要 IV 英文摘要 V 第一章 緒論 1 第二章 文獻回顧 3 第三章 實驗材料與方法 22 第一節 實驗材料 22 第二節 實驗方法 23 第四章 結果 29 第五章 討論 33 第六章 結論與展望 37 參考文獻 51 | |
| dc.language.iso | zh-TW | |
| dc.title | 新抗微管藥物LTP-1在人類胰臟癌細胞之作用機轉探討 | zh_TW |
| dc.title | LTP-1, a Novel Synthetic Arylsulfonamide with Potent and Selective Antimitotic Antitumor Activity against Human Pancreatic Carcinoma in vitro and in vivo | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 99-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 黃德富,顧記華,劉景平,潘秀玲 | |
| dc.subject.keyword | 抗微管,人類胰臟癌, | zh_TW |
| dc.subject.keyword | Antimitotic,Pancreatic Carcinoma, | en |
| dc.relation.page | 57 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2011-07-05 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 目前未授權公開取用 | 4.04 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。